Novartis | NOVN - Gross Profit On Sales


Novartis reported $11.24B in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Alcon AG USD 1.69B 175M Mar/2026
Almirall EUR 429.87M 180.02M Dec/2025
Amgen USD 5.87B 1.02B Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
Autolus Therapeutics Ltd USD 1.65M 2.69M Mar/2026
Bayer EUR 6.33B 1.84B Jun/2026
Biogen USD 2.12B 307M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Fresenius EUR 1.55B 16M Jun/2026
Fresenius Medical Care EUR 1.31B 130.98M Jun/2026
Genmab DKK 1.07B 240M Jun/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
GRIFOLS EUR 704M 84M Jun/2026
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
J&J USD 18.55B 1.31B Jun/2026
Lakefront Biotherapeutics EUR 1.68M 898.68M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.17B 101M Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Novartis USD 10.07B 758M Mar/2026
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Orion EUR 339.9M 85.9M Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Philips EUR 2.15B 384M Jun/2026
Recordati EUR 497.97M 12.85M Jun/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
UCB EUR 3.19B 621M Dec/2025